Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2022 Results Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Maury Raycroft - Jefferies Dae Gon Ha - Stifel Gena Wang - Barclays Joseph Thome - Cowen and Company Swapnil Malekar - Piper Sandler Salveen Richter - Goldman Sachs Luca Issi - RBC Capital Markets Richard Law - Credit Suisse Greg Harrison - Bank of America Mani Foroohar - SVB Leerink Jay Olson - Oppenheimer & Co. Ry Forseth - Guggenheim Partners Kostas Biliouris - BMO Capital Markets Yanan Zhu - Wells Fargo Operator Good morning. And welcome to the Intellia Therapeutics' Second Quarter 2022 Financial Results Conference Call.

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call Transcript

Alnylam Pharmaceuticals

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned appeared first on Investor's Business Daily.

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

Investors are reacting negatively to the company's Q2 update.

Why Intellia Therapeutics Stock Is Sinking Today

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the second quarter ended June 30, 2022.

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Beam Therapeutics

CRISPR Therapeutics

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the entire industry.

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

Recent data from Intellia's Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate. Multiple catalysts from new clinical data releases are seen in the coming quarters and years.

Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely

CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financial results and operational highlights in a conference call on August 4, 2022, at 8 a.m. ET.

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

Coinbase

Fate Therapeutics

MercadoLibre

Teladoc

Tesla

Zoom Video

Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing.

7 Cathie Wood Stocks Trading at a Discount Right Now

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals and Intellia Therapeutics could storm back in the second half of 2022.

2 Biotech Stocks You'll Regret Not Buying on the Dip

Biogen

Editas Medicine

Vertex Pharmaceuticals

Regeneron Pharmaceuticals

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.

7 Moonshot Investments Upending a $10 Trillion Industry

Doximity

Transmedics Group Inc

Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.

Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where treatment with NTLA-2001 resulted in 93% mean and 98% maximum serum TTR reduction by day 28 Intellia to host investor event to discuss updated data from Phase 1 study of NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy today, Friday, June 24, at 8:00 a.m. ET CAMBRIDGE, Mass.

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ: NTLA) with a Market Perform rating and a $54 target price.  The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.

BMO Initiates Coverage On This Gene Editing Spearhead

Exact Sciences

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

5 Health Care Stocks Cathie Wood Favors

CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that interim clinical data from the Phase 1 study of NTLA-2001, an investigational therapy in development for the treatment of transthyretin (ATTR) amyloidosis, will be shared in an oral presentation at the European Association for the Study of the Liver's International Liver Congress™ 2022, taking place June 22 – 26 in London.

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ian Karp - SVP, IR & Corporate Communications John Leonard - President, CEO & Director David Lebwohl - EVP & Chief Medical Officer Laura Sepp-Lorenzino - EVP & Chief Scientific Officer John Hayes - Senior Director, Finance & Controller Glenn Goddard - EVP, CFO & Treasurer Conference Call Participants Swapnil Malekar - Piper Sandler & Co. Maurice Raycroft - Jefferies Dae Gon Ha - Stifel, Nicolaus & Company Salveen Richter - Goldman Sachs Group Joseph Thome - Cowen and Company Gena Wang - Barclays Bank Luca Issi - RBC Capital Markets Mani Foroohar - SVB Leerink Yanan Zhu - Wells Fargo Securities Jay Olson - Oppenheimer Operator Good morning. My name is Drew, and I will be your conference operator today, and welcome to the Intellia Therapeutics First Quarter 2022 earnings conference call.

Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2022 Results - Earnings Call Transcript

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2022.

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

Endo International

Vir Biotechnology

Zoetis

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors.

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the presentation of new preclinical data from its differentiated allogeneic cell engineering platform at Keystone Symposia's Precision Genome Engineering Conference, taking place April 27 – May 1, 2022, in Keystone, Colorado. The data presented support the development of NTLA-6001, Intellia's allogeneic CAR-T development candidate targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin lymphoma (cHL).

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia's Precision Genome Engineering Conference

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financial results and operational highlights in a conference call on May 5, 2022, at 8 a.m. ET.

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

BioNTech SE

The hype has died down. Now it's time for science to take over.

News for Intellia Therapeutics Stock (NTLA)